广济药业(000952) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥180,161,008.71, representing a 56.27% increase compared to ¥115,290,588.81 in the same period last year[5] - The net loss attributable to shareholders was ¥50,508,221.70, which is a 14.69% increase from a loss of ¥44,038,541.85 in the previous year[5] - The net loss for Q1 2024 was ¥54,669,434.50, compared to a net loss of ¥45,398,332.51 in Q1 2023, reflecting a deterioration in performance[20] - The total comprehensive income for the first quarter of 2024 was -54,673,971.69 CNY, compared to -45,395,595.80 CNY in the same period last year, indicating a decline[21] - The company's basic and diluted earnings per share were both -¥0.1427, reflecting a 14.71% decline from -¥0.1244 in the same period last year[5] Cash Flow - The net cash flow from operating activities improved by 23.45%, amounting to -¥48,243,051.48 compared to -¥63,018,293.69 in the prior year[10] - The cash flow from operating activities remains a critical focus area for the company as it navigates through the current financial challenges[20] - Cash inflow from operating activities totaled 281,576,516.95 CNY, up from 159,158,938.29 CNY in the prior year[22] - Cash outflow from operating activities increased to 329,819,568.43 CNY from 222,177,231.98 CNY year-over-year[22] - The net cash flow from investing activities was -26,527,939.59 CNY, compared to -32,887,188.75 CNY in the same period last year[22] - The net cash flow from financing activities was 62,815,258.68 CNY, an increase from 56,711,572.15 CNY year-over-year[22] - The ending balance of cash and cash equivalents was 403,741,511.20 CNY, slightly down from 389,386,320.35 CNY in the previous year[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,013,193,631.25, a decrease of 0.54% from ¥3,029,517,090.67 at the end of the previous year[5] - Total liabilities increased to ¥1,674,641,078.00 from ¥1,637,067,663.82, marking an increase of about 2.3%[17] - The company's total liabilities decreased by 3.65% to ¥1,313,710,382.49 from ¥1,363,446,043.29 at the end of the previous year[5] - The equity attributable to shareholders decreased to ¥1,313,710,382.49 from ¥1,363,446,043.29, a decline of approximately 3.6%[17] Operating Costs - The company's operating costs increased by 59.92% to ¥150,664,862.46, primarily due to increased sales and production costs[9] - Total operating costs for Q1 2024 were ¥239,269,664.37, up from ¥160,483,094.07, indicating an increase of about 48.9%[18] - Management expenses rose by 62.31% to ¥50,216,465.90, attributed to increased losses from projects in Jining and Mengzhou[9] Shareholder Information - Total number of common shareholders at the end of the reporting period is 28,039[13] - The largest shareholder, Changjiang Industrial Investment Group, holds 24.75% of shares, totaling 87,592,065 shares[13] - The company has no changes in the top 10 shareholders due to securities lending or returning[14] Other Financial Metrics - The company received government subsidies amounting to ¥5,709,908.26, a significant increase of 262.32% compared to ¥1,567,640.72 in the previous year[9] - Research and development expenses for Q1 2024 were ¥16,095,943.13, slightly down from ¥16,432,520.06 in the previous year[18] - The company reported a financial expense of ¥8,319,657.53, which increased from ¥5,071,191.99, indicating a rise of approximately 63.5%[18] Strategic Outlook - The company has not disclosed any new strategies or product developments in the current report[14] - The company is exploring new strategies for market expansion and product development to enhance future performance[20] Audit Status - The first quarter report was not audited, indicating that the figures are preliminary and subject to change[23]